1/9/2013 7:46:04 AM
Jeremy Levin did not give a pass to all 46,000 employees of Teva Pharmaceuticals Ltd., but some might be happy to hear that the chief executive officer said Tuesday that reducing "head count" will play only a "small role" in the company's plans to cut $1.5 billion to $2 billion in costs in the next five years. Teva is based in Israel but has its Americas headquarters in North Wales, as well as facilities in Horsham, Frazer, Sellersville, and several New Jersey locations. Indeed, part of Levin's concern since taking over as CEO on May 9 has been that the company has 74 locations in 120 countries and that its efforts were not properly focused. "Not in any way will this be spreading the peanut butter," Levin said in a discussion with stock market analysts Tuesday at the J.P. Morgan Chase Healthcare Conference in San Francisco. Levin was named to his position on Jan. 1, 2012, in part because the Teva stock had languished in recent years. It closed Tuesday up 0.19, at 38.25. Among the projects for which planning "ceased" was a $300 million facility in Northeast Philadelphia that was to serve distribution, warehousing and computer functions. Levin tried again Tuesday to encourage analysts to recommend the stock to clients, though several have said they were lukewarm about the company's generic- and branded-pharmaceuticals pipeline and had no clear indication that the billions in savings would translate into profits. The $6.8 billion purchase of Frazer-based Cephalon in 2011 was one of the larger of the acquisitions that form today's Teva. Though Teva laid off about 1,500 Cephalon employees in Europe almost immediately, acquisitions can add other redundant costs.
comments powered by